Maximizing Investigators' Research Award (MIRA)

Technology Development Program is sponsored by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH). This funding opportunity supports technology research projects from proof-of-concept through prototype development, prioritizing innovation over feasibility. Projects must focus on technological advances and should not include tests of biological hypotheses or biomedical aims.

Maximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional) is sponsored by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH). MIRA provides support for the program of research in an investigator's laboratory that falls within the mission of NIGMS. The goal is to increase funding efficiency by providing investigators with greater stability and flexibility over five-year grant periods, enhancing scientific productivity and the potential for important breakthroughs. This program also aims to distribute funding more widely among talented researchers. Early Stage Investigators should apply through PAR-27-032.

Summary: The fiscal year 2026 (FY26) Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award supports studies that have the potential to make an important contribution to reconstructive transplant research, patient care, and/or quality of life. All projects must demonstrate solid scientific rationale with military-relevant utility. The Investigator-Initiated Research Award does not support clinical trials. Distinctive Features: · Scope: Applications may focus on any phase of research from basic through translational, including preclinical studies in animal models, and clinical research in human subjects or human anatomical substances. · Study Design and Feasibility: The study design should be rigorous and support maximal reproducibility and translational feasibility. A strong statistical plan with appropriate power analysis is important. · Impact: Project results should have the potential for long- and short-term impact on the reconstructive transplant research field and/or patient community. Projects should address at least one of the FY26 RTRP Focus Areas. · Preliminary Data: Preliminary and/or published data that are relevant to reconstructive transplantation and support the rationale for the proposed research must be included. · Military Relevance: All projects must be responsive to the health care needs of military Service Members and/or Veterans recovering from traumatic injury, and/or their Family members, caregivers, or clinicians, as well as the general public. Collaboration with military researchers and clinicians is encouraged but not required. Funding Opportunity Number: HT942526RTRPIIRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8M total program funding.

Summary: The fiscal year 2026 (FY26) Combat Readiness – Medical Research Program (CRRP) Translational Research Award (TRA) supports hypothesis-driven innovative, high-impact translational research that will accelerate the movement of promising ideas and/or technologies in trauma care into solutions to maximize casualty survivability, improve patient care closer to the point of injury and/or trauma care guidelines. Preliminary data are required. Research using well-validated animal models is allowed.Distinctive Features:• **NEW for FY26** An investigator may be named as the Principal Investigator (PI) on only one FY26 CRRP TRA application.• Research supported by the FY26 CRRP TRA must represent a mature, translational research effort with a minimum biomedical technology readiness level (TRL) of 4 or knowledge readiness level (KRL) of 4. Funding Opportunity Number: HT942526CRRPTRA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $4.4M total program funding.